{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:09:35Z","timestamp":1790759375002,"version":"4.1.0"},"reference-count":49,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Pfizer Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biopharmaceutical Statistics"],"DOI":"10.1080\/10543406.2026.2729799","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:06:56Z","timestamp":1789927616000},"page":"1-18","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Leveraging external control for accelerating development: A case study from cell gene therapy in Duchenne muscular dystrophy"],"prefix":"10.1080","author":[{"given":"Huihua","family":"Li","sequence":"first","affiliation":[{"name":"Statistical Research &amp; Data Science Center, Pfizer Inc. New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-3036","authenticated-orcid":false,"given":"Satrajit","family":"Roychoudhury","sequence":"additional","affiliation":[{"name":"Statistical Research &amp; Data Science Center, Pfizer Inc. New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Inflammation &amp; Immunology and Specialty Care Statistics, Pfizer Inc. Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balarama","family":"Gundapaneni","sequence":"additional","affiliation":[{"name":"Inflammation &amp; Immunology and Specialty Care Statistics, Pfizer Inc. Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gamalo","sequence":"additional","affiliation":[{"name":"Inflammation &amp; Immunology and Specialty Care Statistics, Pfizer Inc. Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.17700"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813495959"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1541-0420.2005.00377.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2023.1183101"},{"key":"e_1_3_2_7_1","unstructured":"Biomarin Pharmaceutical. 2017. FDA approves Brineura\u2122 (cerliponase alfa) for the treatment of CLN2 disease a form of Batten disease and ultra-rare pediatric brain disorder in children [Press release]. FDA Approves Brineura\u2122 (cerliponase alfa) for the Treatment of CLN2 Disease a Form of Batten Disease and Ultra-Rare Pediatric Brain Disorder in Children - BioMarin Corporate."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4975"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab158"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-022-00308-6"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02383-3"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1201\/9780429246593"},{"key":"e_1_3_2_14_1","unstructured":"2023. EMA reflection paper on establishing efficacy based on single5 arm trials submitted as pivotal evidence in a marketing authorization."},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.3233\/JND-221527"},{"key":"e_1_3_2_16_1","unstructured":"FDA guidance E9(R1) Statistical Principles for Clinical Trials. 2021. Addendum: estimands and sensitivity analysis in clinical trials. Ang Y McDonald CM Clemens PR gordish HD Illei K Hoffman EP; CINRG DNHS."},{"key":"e_1_3_2_17_1","unstructured":"FDA guidance for industry: Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products. 2023."},{"key":"e_1_3_2_18_1","unstructured":"FDA guidance for industry Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products. 2023."},{"key":"e_1_3_2_19_1","unstructured":"FDA guidance for industry: Long Term Follow-Up After Administration of Human Gene Therapy Products. 2020."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-985X.2004.00349.x"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.4315"},{"key":"e_1_3_2_22_1","volume-title":"Causal inference: what if","author":"Hernan MA","year":"2020","unstructured":"Hernan MA, Robins JM. 2020. Causal inference: what if. Chapman & Hall\/CRC. ISPOR - Use of Machine Learning Techniques to Create External Control Arms: Guidance for Submissions to Health Technologic Assessment. 2024."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-021-00302-y"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09858-8"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00390-5"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009167"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.2466"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2711"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774509356002"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2016.1174149"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-022-00100-2"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(76)90044-8"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1223858"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00011"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-1229-2_14"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1994.10476818"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01862-w"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12974"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242097"},{"key":"e_1_3_2_42_1","unstructured":"U.S. Food and Drug Administration. 2018. FDA granted accelerated approval to blinatumomab for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia [Press release]. FDA granted accelerated approval to blinatumomab (Blincyto Amgen Inc.) for the treatment of adult and pediatric patients with B-cell precursor acute lymphoblastic leukemia | FDA."},{"key":"e_1_3_2_43_1","unstructured":"U.S. Food and Drug Administration. 2019. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia Canada and US [Press release]. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia Canada and US | FDA."},{"key":"e_1_3_2_44_1","volume-title":"FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas [Press release]. Silver Spring, MD: FDA.","author":"U.S. Food and Drug Administration","year":"2020","unstructured":"U.S. Food and Drug Administration. 2020. FDA approves selumetinib for neurofibromatosis type 1 with symptomatic, inoperable plexiform neurofibromas [Press release]. Silver Spring, MD: FDA."},{"key":"e_1_3_2_45_1","unstructured":"van der Laan MJ Rose S. 2011. Causal Inference for Observational and Experimental Data."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004570"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2020.05.002"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3443"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5500"}],"container-title":["Journal of Biopharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10543406.2026.2729799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/10543406.2026.2729799","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10543406.2026.2729799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:49:21Z","timestamp":1790758161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10543406.2026.2729799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":49,"alternative-id":["10.1080\/10543406.2026.2729799"],"URL":"https:\/\/doi.org\/10.1080\/10543406.2026.2729799","relation":{},"ISSN":["1054-3406","1520-5711"],"issn-type":[{"value":"1054-3406","type":"print"},{"value":"1520-5711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=lbps20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}